NRDC Transfers Mosquito Control Larvicidal Formulation Technology to Som Phyto Pharma India Ltd

New Delhi: Dr. H. Purushotham, CMD, National Research Development Corporation, informed that NRDC and  M/s Som Phyto Pharma India Ltd, Hyderabad, have entered into License Agreements for commercialization of Mosquito Larvicidal formulation of Bacillus Thuringiensis Var. Israelensis, an aqueous suspension for killing mosquito at the larval stage. The innovative technology was developed by VCRC, Pondicherry, a laboratory under ICMR, Ministry of Health.

 

Mosquito Larvicidal formulation of Bacillus Thuringiensis Var. Israelensis is proven bio-control agents and has come to be recognized as one of the prime candidates against the larvae of several mosquito species such as Aedes, Anopheles, Culex etc. Bacillus thuringiensis var. israelensis is extremely safe to associate aquatic organisms like copepods, beetles, fishes etc. and beneficial insects like honeybees and silkworms.

 

Extensive field trials as per CIB guidelines have been conducted by the laboratory. The residual activity of the formulation was assessed as per the protocol described by WHO (2005). CIB has already given permanent registration under section 9 (3) of Central Insecticide Board and Registration Committee (CIB&RC) for production of the larvicide, which is mandatory.

 

NRDC has so far licensed this technology to 17 companies in India and contributing to Startup India and Make In India Programme of Government.